|Title||Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.|
|Publication Type||Journal Article|
|Year of Publication||2007|
|Authors||Allen, NE, Key, TJ, Appleby, PN, Travis, RC, Roddam, AW, Rinaldi, S, Egevad, L, Rohrmann, S, Linseisen, J, Pischon, T, Boeing, H, Johnsen, NFøns, Tjønneland, A, Grønbaek, H, Overvad, K, Kiemeney, L, H Bueno-de-Mesquita, B, Bingham, S, Khaw, KTee, Tumino, R, Berrino, F, Mattiello, A, Sacerdote, C, Palli, D, Quirós, JRamón, Ardanaz, E, Navarro, C, Larrañaga, N, González, C, Sánchez, M-J, Trichopoulou, A, Travezea, C, Trichopoulos, D, Jenab, M, Ferrari, P, Riboli, E, Kaaks, R|
|Journal||Cancer Epidemiol Biomarkers Prev|
|Date Published||2007 Jun|
|Keywords||Adult, Aged, Aged, 80 and over, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Humans, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Male, Middle Aged, Neoplasm Staging, Prostatic Neoplasms, Risk Factors|
BACKGROUND: Some studies suggest that elevated serum insulin-like growth factor (IGF)-I concentrations are associated with an increased risk of prostate cancer and, in particular, with an increased risk of advanced-stage prostate cancer.
METHODS: We analyzed the association between prediagnostic serum concentrations of IGF-I and IGF-binding protein-3 (IGFBP-3) and prostate cancer risk in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition. This study includes 630 incident prostate cancer cases and 630 matched control subjects. Odds ratios and their 95% confidence intervals (95% CI) were calculated for prostate cancer risk associated with increasing IGF-I and IGFBP-3 concentrations using conditional logistic regression.
RESULTS: The risk of total prostate cancer in the highest versus the lowest third of serum peptide concentration was 1.35 (95% CI, 0.99-1.82; Ptrend = 0.08) for IGF-I, 1.39 (95% CI, 1.02-1.89; Ptrend = 0.12) for the IGF-I residuals after adjusting for IGFBP-3, 1.22 (95% CI, 0.92-1.64; Ptrend = 0.38) for IGFBP-3, and 1.01 (95% CI, 0.74-1.37; Ptrend = 0.75) for the IGFBP-3 residuals after adjusting for IGF-I. There was no significant difference in the association of peptide hormones and prostate cancer by stage of disease, although the association of serum IGF-I concentration with risk was slightly stronger for advanced-stage disease; the odds ratio for the highest versus the lowest third was 1.65 (95% CI, 0.88-3.08; Ptrend = 0.21) for IGF-I and 1.76 (95% CI, 0.92-3.40; Ptrend = 0.11) for IGF-I adjusted for IGFBP-3.
CONCLUSIONS: In this large nested case-control study, serum IGF-I concentration is not strongly associated with prostate cancer risk, although the results are compatible with a small increase in risk, particularly for advanced-stage disease; no association for IGFBP-3 was observed.
|Alternate Journal||Cancer Epidemiol. Biomarkers Prev.|
|Grant List||G0401527 / / Medical Research Council / United Kingdom |
U01 CA098216-01 / CA / NCI NIH HHS / United States
/ / Wellcome Trust / United Kingdom